Vaccines Market: Meticulous Research Reveals Why This Market is growing at a CAGR of 7.9% to Reach USD 57,501.8 Million by 2025

Vaccines represent one of the greatest achievements of science and medicine in the fight against infectious diseases. Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. Significant progress has been made in expanding the coverage of vaccines globally, resulting in the prevention of more than two million deaths annually. Meticulous Research(R) in its latest publication on vaccines market states that the global vaccines market will increase at a CAGR of 7.9% from 2018 to 2025 to reach USD 57,501.8 million by 2025.

Get Free sample report here: https://www.meticulousresearch.com/request-sample-report/?cp_id=4813

The growth of the global vaccines market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancement in vaccine industry, and strong pipeline for vaccines. Furthermore, the increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market.

To provide efficient analysis, Meticulous Research has segmented this market on the basis of indication (pneumococcal, influenza, DTP, HPV, hepatitis, meningococcal, rotavirus, polio, MMR), type (live, toxoid), route of administration (IM, SC, oral), valence (monovalent, multivalent), and geography.

Wherein, geographically, North America commanded the largest share in this market followed by Europe. The major share of North America is mainly attributed to its well established vaccination programs, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players.

While in terms of indication, pneumococcal disease accounted for the largest share in the global vaccines market in 2017. The large share of this segment is mainly attributed to high prevalence of pneumococcal disease in pediatric, elderly, and immune compromised populations. In addition, growing number of pneumococcal diseases resulting in chronic illnesses is further driving the adoption of the pneumococcal vaccines globally.

Browse detailed TOC @ https://www.meticulousresearch.com/product/vaccines-market/

The report provides competitive intelligence in terms of financials, growth strategies, product portfolios, and geographical presence on some of the key players in this market including GSK, Merck & Co., Inc., Pfizer, and Sanofi, CSL Limited, Emergent BioSolutions, Johnson and Johnson, Serum Institute of India, Daiichi Sankyo, Takeda, and AstraZeneca.

Vaccines Market by Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR), Type (Live, Toxoid), Route of Administration (IM, SC, Oral), Valence (Monovalent, Multivalent) And Geography - Global Forecast To 2025

Key Topics Covered in This Report:

1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Industry Analysis
6. Global Vaccines Market, by Indication
7. Global Vaccines Market, by Route of Administration
8. Global Vaccines Market, by Type/Antigen
9. Global Vaccines Market, by Valence
10. Vaccines Market, by Region
11. Competitive Landscape
12. Company Profiles
13. Appendix

Get Free sample report here: https://www.meticulousresearch.com/request-sample-report/?cp_id=4813

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Contact –
Meticulous Research
Khushal Bombe
sales@meticulousresearch.com
Office No-402, 4th Floor,
Pushpak Business Hub,
Wakad, Pimpri-Chinchwad, 411057 India.
Direct Lines: on
+91 744-778-0008
1–646–781–8004

This release was published on openPR.